European Pharmaceutical Review

FEBRUARY 13, 2025

According to Orion Corporation, based on these estimates, the directive could make it unprofitable for pharmaceutical companies to maintain their current range of medicines. The post EU Urban Wastewater Treatment Directive may compromise EU medicine availability appeared first on European Pharmaceutical Review.

Medicine 59

Medicine Pharmaceutical manufacturing Manufacturing Competition 59

European Pharmaceutical Review

OCTOBER 14, 2022

Amgen’s 2022 market report has detailed how competition has driven savings across healthcare, estimating that a considerable number of biologics will be in competition with biosimilars in five to 10 years. A rise in savings per quarter was recognised in this year’s data.

Competition 97

Competition Healthcare Healthcare Food and Drug Administration 97

pharmaphorum

OCTOBER 7, 2022

It’s often stated – mostly without reference to data – that the environment for innovative launches is more competitive now than it ever has been. Continued competitive intensity. The first in class launches barely have time to establish before they face competition, and then the competition keeps on coming.

Competition 93

Competition Marketing Medicine Pharmaceutical 93

European Pharmaceutical Review

JULY 7, 2023

New recommendations to boost the competitiveness in UK biopharma and Medtech sectors have been published by Imperial College London. The ‘Sectoral Systems of Innovation and the UK’s Competitiveness’ reports assess the value-added per capita of each sector and how they compare internationally.

Competition 104

Competition Biopharma Government Manufacturing 104

European Pharmaceutical Review

SEPTEMBER 4, 2023

to address the potential competitive harm Amgen’s $27.8 Consolidation in the pharmaceutical industry has given companies the power and incentive to engage in exclusionary rebating practices, which can lead to sky-rocketing prices on essential medications,” stated Henry Liu, Director of the FTC’s Bureau of Competition.

Competition 98

Competition Biopharma Pharmaceutical Government 98

Fierce Pharma

JUNE 2, 2023

As Bristol Myers Squibb braces for increasing generic competition this decade, the company is counting on its newer medicines to drive growth. | As Bristol's top-sellers creep toward the patent cliff, new launch Camzyos has picked up a key endorsement in England.

Competition 182

Competition Sales Medicine 182

pharmaphorum

JANUARY 24, 2023

Drastic steps need to be taken if the UK is to reverse a steep decline in medicines manufacturing in recent years, according to a cross-industry coalition. Since 2010, the UK has fallen from 4th to 98th place in overall trade balance in pharmaceuticals, due to fierce global competition, according to the MMIP. It’s not all bad news.

Manufacturing 111

Manufacturing Medicine Government Pharmaceutical manufacturing 111

European Pharmaceutical Review

FEBRUARY 2, 2023

While maintaining a healthy manufacturing industry for production of ‘high tech’ pharmaceuticals, Europe has stepped away from manufacturing essential medicines and active pharmaceutical ingredients (APIs) due to unrelenting price pressures and is now heavily reliant on the import of these critical ingredients.

Medicine 111

Medicine Manufacturing Pharmaceutical Specialization 111

European Pharmaceutical Review

JANUARY 29, 2024

According to Medicines for Europe, the Munich District Court’s Supplementary Protection Certificate (SPC) manufacturing waiver , issued in Germany in October 2023, is “in conflict” with the objectives of the waiver. ” This threatens investments in manufacturing, according to Medicines for Europe.

Medicine 98

Medicine Manufacturing Competition Marketing 98

PM360

JUNE 26, 2023

Access to medicines have persisting and systemic differences across the globe and within countries. It is estimated that nearly two billion people globally do not have access to essential medicines. Traditionally, pharmaceutical companies have not prioritized emerging markets as part of their access strategy.

Medicine 98

Medicine Marketing Pharma Manufacturing 98

Evolve Your Success

NOVEMBER 14, 2023

One of those is sports medicine. As we celebrate International Men’s Day, Samuel Adeyinka interviews Jordan Rawlins about the world of orthopedics, namely sports medicine. What are the different roles in sports medicine medical sales and what do you need to prepare to ensure success in this space? What are you selling?

Medical sales 130

Medical sales Medicine Sales Medical 130

European Pharmaceutical Review

JULY 19, 2024

Key areas included in the Political Guidelines Increasing competitiveness Harnessing innovation–covering digital, collaboration, strategy and more—was conveyed as a vital component for improving European competitiveness. As such, she noted that the initial priority will be “prosperity and competitiveness.”

Competition 52

Competition Medicine Pharmaceutical Manufacturing 52

PM360

AUGUST 24, 2023

In our healthcare space, however, improved understanding and practice of diversity is required and urgent—and the only way we’ll advance medicine equitably. We have in front of us a unique opportunity to not only appreciate but harness the power of generational diversity as a competitive advantage. To be sure, steps have been taken.

Competition 98

Competition Marketing Healthcare Healthcare 98

European Pharmaceutical Review

FEBRUARY 20, 2025

New analysis from Teva Pharmaceuticals Europe has reported concerning statistics regarding the security of critical medicines supply in the region is at risk. For instance, in the EU, 46 percent of generic medicines from the EU Critical List of Medicines are provided by a single supplier.

Medicine 59

Medicine Manufacturing Marketing Healthcare 59

European Pharmaceutical Review

JANUARY 31, 2025

Over 100 biosimilar medicines are approved for nearly 30 reference medicines, testimony to the rigour of the scientific standards leading to the European authorisation process. Biological medicines represent 41 percent of pharmaceutical spending, growing at three times the rate of chemical medicines.

Medicine 52

Medicine Competition Marketing Patients 52

European Pharmaceutical Review

NOVEMBER 30, 2023

A report by Act4Biosimilars published earlier this month, highlighted that to support the adoption of these medicines and widen patient access across Europe, measures must be put in place to lower the financial burden of developing these medicines. Furthermore, since the launch of biosimilars these provided nearly 4.5

Marketing 111

Marketing Medicine Competition Distribution 111

pharmaphorum

AUGUST 17, 2022

The latest life science competitiveness indicators (LSCIs) were published by the Office of Life Sciences (OLS) in July 2022. The median number of days between marketing authorisation and medicines being made available is included too.

Competition 59

Competition Medicine Patients Government 59

Pharma Marketing Network

NOVEMBER 23, 2024

From AI-powered insights to the rise of precision medicine, new trends are reshaping the way we connect with patients and healthcare providers. Precision Medicine: Targeting the Right Audience Precision medicine, with its focus on individualized treatment, offers a goldmine of opportunities for marketers.

Marketing 52

Marketing Pharma Ethics Healthcare Provider 52

Healthcare Success

DECEMBER 2, 2024

7 Ways Your Value Proposition Helps Grow Your Healthcare Business Marked by disruptors and innovations like telehealth, advancing technologies, and evolving consumer expectations, the healthcare industry has become more competitive than ever. A good brand reputation can help elevate your brand in a competitive environment.

Patients 59

Patients Marketing Competition Healthcare 59

European Pharmaceutical Review

NOVEMBER 16, 2023

With procurement practices across Europe having a strong price focus, over time, this could impact the “sustainability of biosimilars and decrease competition, as well as reducing supply reliability”, the report acknowledged. “As Act4Biosimilars is supported by its founding sponsor, Sandoz.

Marketing 110

Marketing Education Competition Consulting 110

European Pharmaceutical Review

OCTOBER 10, 2024

A draft joint EU network strategy to 2028 has been published by the European Medicines Agency (EMA) and the Heads of Medicines Agencies (HMA). The EMA highlighted that advances in technology such as artificial intelligence (AI) has created opportunities to transform medicine development and regulation.

Medicine 98

Medicine Networking Competition Pharmaceutical 98

Pharma Marketing Network

OCTOBER 23, 2024

It’s about knowing what the market wants, understanding your competition, and predicting the next trend before it happens. In this article, we’ll break it down, explaining how you can leverage market research to not just survive but thrive in the ever-competitive pharma world. That’s where competitive analysis comes in.

Competition 52

Competition Marketing Pharma Medical 52

Eversana Intouch

JANUARY 28, 2025

Mastering localization and avoiding cultural blind spots are crucial, and navigating global regulations is a competitive advantage for brands that do it well. AI tools will continue to boost efficiency, predict future trends, revolutionize medicine delivery and strengthen global connections.

Marketing 59

Marketing Pharma Education Ethics 59

European Pharmaceutical Review

APRIL 28, 2023

Several industry bodies have commented on the proposal, including the European Federation of Pharmaceutical Industries and Associations (EPFIA) and Alliance for Regenerative Medicine (ARM) as well as law firm Pinset Masons.

Pharmaceutical 98

Pharmaceutical Pharma Medicine Competition 98

European Pharmaceutical Review

APRIL 11, 2024

Over the past few years, the biosimilar market has expanded “rapidly” due to these medicines offering a cost-effective alternative to the reference product. This has resulted in “increased competition and price pressure, driving the growth of the biosimilar market”. million by 2032, at 17.6 percent CAGR between 2023 and 2032.

Marketing 105

Marketing Competition Manufacturing Medicine 105

pharmaphorum

OCTOBER 26, 2022

Drugmakers Pfizer and Flynn Pharma have formally launched an appeal against a £70 million ($84 million) fine levied by the UK Competition and Markets Authority (CMA) for overcharging the NHS for a widely-used epilepsy drug. The CAT typically takes around nine months to deliver a verdict, although it can take longer in more complicated cases.

Competition 105

Competition Marketing Pharma Medicine 105

European Pharmaceutical Review

JANUARY 11, 2024

billion, so biosimilar competition could significantly expand patient access to this biologic therapy within the fields of gastroenterology, dermatology, and rheumatology, according to STADA and Alvotech. The EU ustekinumab market is worth €2.5

Competition 115

Competition Marketing Safety Manufacturing 115

European Pharmaceutical Review

OCTOBER 4, 2023

Going forward, the company will continue to focus on developing generic and biosimilar medicines for the European medicines market, with focus on sustainable access. According to Sandoz, generics and biosimilar treatments account for an estimated 80 percent of medicines used globally by volume.

Medicine 105

Medicine CRM Pharmaceutical Competition 105

Evolve Your Success

MARCH 12, 2025

That’s a very it’s an extremely competitive space where there are other spaces and they may have no competitor. You’re the only device that solves that problem, so your need to sell isn’t as strong as when you’re working in maybe a more competitive space where there’s a lot of me too products.

Medical sales 130

Medical sales Sales Medical Patients 130

European Pharmaceutical Review

SEPTEMBER 28, 2023

According to the European Federation of Pharmaceutical Industries and Associations (EFPIA), more than 600 essential medicines are at risk if a proposed restriction on the use of fluorinated substances, per- and polyfluoroalkyl substances (PFAS) across pharmaceutical manufacturing in the EEA, is implemented.

Pharmaceutical manufacturing 105

Pharmaceutical manufacturing Manufacturing Pharmaceutical Medicine 105

pharmaphorum

NOVEMBER 16, 2022

Novartis has already spun out its eyecare business Alcon, and is now considering the sale of its ophthalmology and respiratory medicines businesses as it continues a narrowing of its focus, according to media reports. Meanwhile, Lucentis sales have been in decline as a result of biosimilar competition, contracting 11% to $1.55

Sales 124

Sales Prescription Medicine Media 124

Evolve Your Success

MARCH 28, 2024

Chad is currently the Vice President of Sports Medicine, Extremities, Trauma, and ASC strategy for Zimmer Biomet Carolinas. Discover what it takes to make it in the high-stakes arenas of sports medicine, trauma, and orthopedics. He is a successful sales executive with over 23 years of experience.

Sales 130

Sales Medical Medical sales Sales process 130

European Pharmaceutical Review

JULY 25, 2023

The small molecule API market is influenced by several factors, including heightened R&D within the pharmaceutical sector, a growing prevalence of chronic illnesses and rising demand for generic medicines. Other molecule types Small molecule API manufacturers are in fierce competition with medicines such as biologics, the report stated.

Marketing 97

Marketing Manufacturing Competition Pharmaceutical 97

World of DTC Marketing

APRIL 20, 2022

This was especially true with new drugs that have a significant competitive market. However, it seems that medical liaisons provide a lot of the value supplied they have some type of medical background and can talk to them peer to peer. They want more access to medical liaisons, including talking with them via video chats and email.

Marketing 218

Marketing Pharma Insurance Medical 218

PM360

MARCH 12, 2025

Nuvera is a leading consulting firm dedicated to designing, building, and measuring patient and HCP treatment experiences for rare diseases, specialty medicines, and cell and gene therapeutics. For 15 years, Nuvera has helped clients enhance specialty product engagement by delivering data-driven patient experience solutions.

Patients 52

Patients Consulting Competition Management 52

World of DTC Marketing

JUNE 1, 2021

Kesselheim, a professor of medicine at Harvard Medical School via the Washington Post , says “the worst thing for people with Alzheimer’s would be to put out a product that doesn’t work.” SUMMARY: The FDA is coming under intense pressure to approve Biogen’s Alzheimer’s drug, but Aaron S.

FDA 187

FDA Side effects Patients Doctors 187

pharmaphorum

OCTOBER 5, 2022

As our understanding has advanced, we now know that we often need more than one medicine, with more than one mode of action, to target the different underlying mechanics of disease,” she says. The challenge we face in the UK is the way NICE and the Scottish Medicines Consortium use cost effectiveness to assess combination therapies.”.

Medicine 98

Medicine Competition Patients Marketing 98